Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.46 |
| ▸ | TLR2 | O60603 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929242 | 1.00 | SIRT2 (0.46) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL3939473 | 1.00 | SIRT2 (0.46) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL3936778 | 1.00 | SIRT2 (0.46) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL3939841 | 1.00 | SIRT2 (0.46) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL3930451 | 1.00 | SIRT2 (0.46) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL3929753 | 1.00 | SIRT2 (0.46) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL3936777 | 1.00 | SIRT2 (0.46) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL2678812 | 0.88 | SIRT2 (0.51) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL28993230 | 0.87 | SIRT2 (0.45) | SIRT2SIRT1MEN1ALDH1A1HPGD | |
| SCHEMBL11196365 | 0.85 | MEN1 (0.52) | SIRT2SIRT1MEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541020-B2 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-7063967-B2 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| EP-0983286-B1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORP (US) | 2004-07-28 | — | — | EP | disclosed |
| US-6764840-B2 | AUGMENT ANTIBODY PRODUCTION IN IMMUNIZED ANIMALS AS WELL AS STIMULATE CYTOKINE PRODUCTION AND ACTIVATE MACROPHAGES. | CORIXA CORPORATION | 2004-07-20 | — | — | US | disclosed |
| US-20030199460-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2003-05-15 | — | — | US | disclosed |
| EP-1230250-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-6355257-B1 | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6303347-B1 | VACCINES | CORIXA CORPORATION | 2001-10-16 | — | — | US | disclosed |
| WO-2001034617-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199460-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | SIRT2 4338/4885SIRT1 4744/4885MEN1 4284/4885 |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | SIRT2 4253/4885SIRT1 4700/4885MEN1 4335/4885 |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | SIRT2 4338/4885SIRT1 4744/4885MEN1 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.